Small Molecule Compounds Enhance Oncolytic Virus Spread
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic virus therapies face challenges in efficiently spreading within tumors due to their attenuated growth, which limits their effectiveness, and existing compounds like HDIs can cause toxicities, necessitating the identification of alternative molecules to enhance viral efficacy.
Innovation Solution
The use of specific compounds such as 3,4-dichloro-5-phenyl-2,5-dihydrofuran-2-one (DCPDF) and other listed compounds to increase virus production and spread in cancer cells, specifically enhancing oncolytic viral efficacy by administering them prior to, with, or after the virus, thereby overcoming anti-viral defenses and improving cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If oncolytic viruses are genetically modified or selected for attenuated growth, then safety in normal host tissues is improved, but spread within tumor cells is reduced
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to bridge the gap between safety and efficacy. These compounds selectively enhance viral spread in tumor cells without compromising the attenuated nature of the virus in normal tissues, acting as a mediator that enables controlled enhancement of oncolytic activity while maintaining safety profile
Solution Approach 2:
The invention changes the local parameters within tumor cells by introducing small molecule compounds that modify the cellular environment to favor viral replication and spread. This allows the virus to exert its full oncolytic potential specifically in tumor cells while remaining attenuated in normal host tissues
2Productivity
If histone deacetylase inhibitors are continuously administered to enhance viral spread, then oncolytic efficacy is improved, but toxicity increases
Solution Approach 1:
The patent employs short-acting small molecule compounds that provide transient enhancement of viral spread. These compounds are administered briefly to initiate enhanced viral replication, then eliminated, avoiding the cumulative toxicity associated with continuous HDI administration while maintaining the beneficial effect on viral spread
Solution Approach 2:
The invention implements periodic administration of small molecule compounds to enhance viral spread. Rather than continuous dosing, the compounds are administered in periodic pulses that coincide with viral replication cycles, providing sustained enhancement while allowing clearance periods that reduce toxicity accumulation
3Productivity
If compounds are used to enhance virus production, then oncolytic efficacy is improved, but complexity of treatment protocol increases
Solution Approach 1:
The patent combines the administration of small molecule compounds with viral delivery into a single integrated treatment protocol. The compounds are co-administered with the oncolytic virus, merging two therapeutic elements into one unified treatment approach that enhances virus production without requiring separate, complex administration steps
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are viral sensitizing compounds that enhance the efficacy of viruses by increasing spread of the virus in cells, increasing the titer of virus in cells, or increasing the cytotoxicity of virus to cells. Other uses, compositions and methods of using same are also provided.